ABSTRACT
Patients with type 2 diabetes vary in their response to currently available therapeutic agents (including GLP-1 receptor agonists) leading to suboptimal glycemic control and increased risk of complications. We show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM), as well as Pam-knockout mice, display increased resistance to GLP-1 in vivo. Pam inactivation in mice leads to reduced gastric GLP-1R expression and faster gastric emptying: this persists during GLP-1R agonist treatment and is rescued when GLP-1R activity is antagonized, indicating resistance to GLP-1’s gastric slowing properties. Meta-analysis of human data from studies examining GLP-1R agonist response (including RCTs) reveals a relative loss of 44% and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphic PAM alleles p.S539W and p.D536G treated with GLP-1R agonist. Genetic variation in PAM has effects on incretin signaling that alters response to medication used commonly for treatment of T2D.
(Funded by the Wellcome, Medical Research Council, European Union, NIHR Oxford Biomedical Research Centre, United Kingdom, Registered on ClinicalTrials.gov, NCT02723110.)
Summary Paragraph Type 2 diabetes (T2D) is a leading cause of morbidity and mortality globally1. Current management of T2D patients focuses on lowering glycemic exposure and reducing complications with lifestyle and pharmacological interventions2. Despite the availability of multiple medications to lower glycated hemoglobin (HbA1c), only 53% of individuals with T2D reach the glycemic target (HbA1c <7%)3, 4. There is potential to improve medication selection through “precision medicine” where patient specific factors (e.g. genetic markers) are used to indicate whether a patient is more or less likely to respond to a medication. Here we show that human carriers of hypomorphic T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM), as well as Pam-knockout mice, have reduced PAM enzyme activity, display increased resistance to glucagon like peptide 1 (GLP-1) in vivo and have reduced response to the GLP-1 receptor agonist. Meta-analysis of human data from studies examining GLP-1 receptor agonist response (including RCTs) reveals a relative loss of 44% and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphic PAM alleles p.S539W and p.D536G treated with GLP-1 receptor agonist. Genetic variation in PAM has effects on incretin signaling that alters response to medication used commonly for treatment of T2D.
Competing Interest Statement
ERP has received honoraria from Lilly, Sanofi and Illumina. MIM holds stock options in Roche. ALG's spouse is an employee of Genentech and holds stock options in Roche.
Funding Statement
ALG is a Wellcome Trust Senior Fellow in Basic Biomedical Science. MIM was a Wellcome Senior Investigator and NIHR Senior Investigator. ERP was a Wellcome Trust New Investigator (102820/Z/13/Z). BH is supported by a Diabetes UK RD Lawrence Fellowship 19/0005965. This work was funded by the Wellcome Trust (095101 [ALG], 200837 [ALG], 098381 [MIM], 106130 [ALG, MIM], 203141 (ALG, MIM], 203141 [MIM]), Medical Research Council (MR/L020149/1) [MIM, ALG, FK, ATH], European Union Horizon 2020 Programme (T2D Systems) [ALG, TH], and NIH (U01-DK105535; U01-DK085545) [MIM, ALG] and UM-1DK126185 [ALG], the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) [ALG, MIM, FK]. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The study was supported by the Novo Nordisk Foundation (Grant number NNF18CC0034900). The study was supported by a grant by Boehringer Ingelheim (MS). The work leading to this publication has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no.115317 (DIRECT), resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. This publication is based on research using data from GSK (HARMONY trials) that has been made available through secured access. GSK has not contributed to or approved, and is not in any way responsible for, the contents of this publication. We thank both GSK and www.ClinicalStudyDataRequest.com for providing us data and access. The ADDITION-PRO study was funded by an unrestricted grant from the European Foundation for the Study of Diabetes/Pfzer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801), by the Danish Council for Strategic Research and by internal research and equipment funds from Steno Diabetes Center. This work was supported by the European Union's Horizon 2020 research and Innovation programme (Grant Agreement No 667191). AJ is supported by the Danish Council for Independent Research, European Union, FP7, Marie Curie Actions, IEF, Lundbeck Foundation (R140-2013-13313), Novo Nordisk Foundation and Danish Diabetes Academy (NNF17SA0031406, PDMI002-18) The PRIBA study was funded by A National Institute for Health and Care Research (U.K.) Doctoral Research Fellowship (DRF-2010-03-72, Jones) and supported by the National Institute for Health Research and Care Clinical Research Network. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All volunteers provided written informed consent. The protocol was approved by Oxford B NRES Research Ethics Committee. The study was registered prospectively (ClinicalTrials.gov:NCT02723110).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
All other data generated or analysed during this study are included in this published article (and its supplementary information files). IMI-DIRECT data access is available on request (DIRECTdataaccess{at}dundee.ac.uk). HARMONY data can be requested via clinicalstudydatarequest.com. De-identified participant-level data generated in this study from the Oxford Biobank can be requested from the corresponding author pending approval from the Oxford Biobank.